The potential to target CCL5/CCR5 in breast cancer

Bibliography

• Forman D, Ferlay J. The global and regional burden of cancer. In: Stewart BW, Wild CP, editors, World Cancer Report 2014. International Agency for Research on Cancer, Lyon, France; 2014. p. 64-185
   Google Scholar
• Breast Cancer. National Cancer Institute. Available from: http://www.cancer.gov/cancertopics/types/breast [23 April 2014]
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
   PubMed Web of Science ®Google Scholar
• Boyle P. Breast cancer control: signs of progress, but more work required. Breast 2005;14:429-38
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-7
   PubMed Web of Science ®Google Scholar
• Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 2014;32:659-702
   PubMed Web of Science ®Google Scholar
• Marques RE, Guabiraba R, Russo RC, Teixeira MM. Targeting CCL5 in inflammation. Expert Opin Ther Targets 2013;17:1439-60
   PubMed Web of Science ®Google Scholar
• Velasco-Velazquez M, Jiao X, De La Fuente M, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012;72:3839-50
   PubMed Web of Science ®Google Scholar
• Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6
   PubMed Web of Science ®Google Scholar
• Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-13
   PubMed Web of Science ®Google Scholar
• Ginestier C, Liu S, Diebel ME, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010;120:485-97
   PubMed Web of Science ®Google Scholar
• Wu K, Katiyar S, Li A, et al. Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8. Proc Natl Acad Sci USA 2008;105:6924-9
   PubMed Web of Science ®Google Scholar
• Appay V, Rowland-Jones SL. RANTES: a versatile and controversial chemokine. Trends Immunol 2001;22:83-7
   PubMed Web of Science ®Google Scholar
• Levy JA. The unexpected pleiotropic activities of RANTES. J Immunol 2009;182:3945-6
   PubMed Web of Science ®Google Scholar
• Pakianathan DR, Kuta EG, Artis DR, et al. Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. Biochemistry 1997;36:9642-8
   PubMed Web of Science ®Google Scholar
• Juremalm M, Olsson N, Nilsson G. Selective CCL5/RANTES-induced mast cell migration through interactions with chemokine receptors CCR1 and CCR4. Biochem Biophys Res Commun 2002;297:480-5
   PubMed Web of Science ®Google Scholar
• Ignatov A, Robert J, Gregory-Evans C, Schaller HC. RANTES stimulates Ca2+ mobilization and inositol trisphosphate (IP3) formation in cells transfected with G protein-coupled receptor 75. Br J Pharmacol 2006;149:490-7
   PubMed Web of Science ®Google Scholar
• Gardner L, Patterson AM, Ashton BA, et al. The human Duffy antigen binds selected inflammatory but not homeostatic chemokines. Biochem Biophys Res Commun 2004;321:306-12
   PubMed Web of Science ®Google Scholar
• Nibbs RJ, Wylie SM, Yang J, et al. Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6. J Biol Chem 1997;272:32078-83
   PubMed Web of Science ®Google Scholar
• Leick M, Catusse J, Follo M, et al. CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B. Immunology 2010;129:536-46
   PubMed Web of Science ®Google Scholar
• Luboshits G, Shina S, Kaplan O, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999;59:4681-7
   PubMed Web of Science ®Google Scholar
• Niwa Y, Akamatsu H, Niwa H, et al. Correlation of tissue and plasma RANTES levels. with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001;7:285-9
   PubMed Web of Science ®Google Scholar
• Luboshits G, Shina S, Kaplan O, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999;59:4681-7
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yao F, Yao X, et al. Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep 2009;21:1113-21
   PubMed Web of Science ®Google Scholar
• Jiao X, Katiyar S, Willmarth NE, et al. c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem 2010;285:8218-26
   Google Scholar
• Stormes KA, Lemken CA, Lepre JV, et al. Inhibition of metastasis by inhibition of tumor-derived CCL5. Breast Cancer Res Treat 2005;89:209-12
   PubMed Web of Science ®Google Scholar
• Korkaya H, Kim GI, Davis A, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 2012;47:570-84
   PubMed Web of Science ®Google Scholar
• Manes S, Mira E, Colomer R, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003;198:1381-9
   PubMed Web of Science ®Google Scholar
• Murooka TT, Rahbar R, Fish EN. CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation. Biochem Biophys Res Commun 2009;387:381-6
   PubMed Web of Science ®Google Scholar
• Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006;66:124-34
   PubMed Web of Science ®Google Scholar
• Ertel A, Dean JL, Rui H, et al. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 2010;9:4153-63
   PubMed Web of Science ®Google Scholar
• Zhang Y, Meng FY, Li WL, et al. Association of chemotactic factor receptor 5 gene with breast cancer. Genet Mol Res 2013;12:5289-300
   PubMed Web of Science ®Google Scholar
• Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008;111:4233-44
   PubMed Web of Science ®Google Scholar
• Gallo M, De Luca A, Lamura L, Normanno N. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol 2012;23:597-604
   Google Scholar
• Wu FY, Ou ZL, Feng LY, et al. Chemokine decoy receptor d6 plays a negative role in human breast cancer. Mol Cancer Res 2008;6:1276-88
   PubMed Web of Science ®Google Scholar
• Yang C, Yu KD, Xu WH, et al. Effect of genetic variants in two chemokine decoy receptor genes, DARC and CCBP2, on metastatic potential of breast cancer. PLoS ONE 2013;8:e78901
   Web of Science ®Google Scholar
• Swamydas M, Ricci K, Rego SL, Dreau D. Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases. Cell Adh Migr 2013;7:315-24
   PubMed Web of Science ®Google Scholar
• Tao K, Fang M, Alroy J, Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 2008;8:228
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-63
   PubMed Web of Science ®Google Scholar
• Locati M, Deuschle U, Massardi ML, et al. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J Immunol 2002;168:3557-62
   PubMed Web of Science ®Google Scholar
• Robinson SC, Scott KA, Balkwill FR. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol 2002;32:404-12
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307
   PubMed Web of Science ®Google Scholar
• Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory T cells in cancer. Adv Cancer Res 2010;107:57-117
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Rooney C, Dotti G, Savoldo B. Changes in chemokine receptor expression of regulatory T cells after ex vivo culture. J Immunother 2012;35:329-36
   PubMed Web of Science ®Google Scholar
• Tan MC, Goedegebuure PS, Belt BA, et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009;182:1746-55
   PubMed Web of Science ®Google Scholar
• Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009;69:2000-9
   PubMed Web of Science ®Google Scholar
• Razmkhah M, Jaberipour M, Safaei A, et al. Chemokine and chemokine receptors: a comparative study between metastatic and nonmetastatic lymph nodes in breast cancer patients. Eur Cytokine Netw 2012;23:72-7
   PubMed Web of Science ®Google Scholar
• Takenaka M, Seki N, Toh U, et al. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol 2013;1:625-32
   PubMedGoogle Scholar
• Demir L, Yigit S, Ellidokuz H, et al. Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs. Clin Exp Metastasis 2013;30:1047-62
   PubMed Web of Science ®Google Scholar
• Li YQ, Liu FF, Zhang XM, et al. Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer. PLoS One 2013;8:e76379
   PubMed Web of Science ®Google Scholar
• Umansky V, Sevko A. Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron 2013;6:169-77
   PubMedGoogle Scholar
• Markowitz J, Wesolowski R, Papenfuss T, et al. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat 2013;140:13-21
   PubMed Web of Science ®Google Scholar
• Schlecker E, Stojanovic A, Eisen C, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 2012;189:5602-11
   PubMed Web of Science ®Google Scholar
• Tsutsui S, Yasuda K, Suzuki K, et al. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 2005;14:425-31
   PubMed Web of Science ®Google Scholar
• Fujimoto H, Sangai T, Ishii G, et al. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer 2009;125:1276-84
   PubMed Web of Science ®Google Scholar
• Mi Z, Bhattacharya SD, Kim VM, et al. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 2011;32:477-87
   PubMed Web of Science ®Google Scholar
• Chaturvedi P, Gilkes DM, Wong CC, et al. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest 2013;123:189-205
   PubMed Web of Science ®Google Scholar
• Jayasinghe MM, Golden JM, Nair P, et al. Tumor-derived CCL5 does not contribute to breast cancer progression. Breast Cancer Res Treat 2008;111:511-21
   PubMed Web of Science ®Google Scholar
• Wilkin TJ, Su Z, Krambrink A, et al. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr 2010;54:470-6
   Google Scholar
• Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-32
   PubMed Web of Science ®Google Scholar
• Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008;197:262-5
   PubMed Web of Science ®Google Scholar
• Lim JK, Murphy PM. Chemokine control of West Nile virus infection. Exp Cell Res 2011;317:569-74
   PubMed Web of Science ®Google Scholar
• Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008;197:266-9
   PubMed Web of Science ®Google Scholar
• Petersen DC, Severi G, Hoang HN, et al. No association between common chemokine and chemokine receptor gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:3615-17
   PubMed Web of Science ®Google Scholar
• Khademi B, Razmkhah M, Erfani N, et al. SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. Pathol Oncol Res 2008;14:45-50
   PubMed Web of Science ®Google Scholar
• Robinson SC, Scott KA, Wilson JL, et al. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003;63:8360-5
   PubMed Web of Science ®Google Scholar
• Kuo CH, Liu CJ, Lu CY, et al. 17beta-estradiol inhibits mesenchymal stem cells-induced human AGS gastric cancer cell mobility via suppression of CCL5- Src/Cas/Paxillin signaling pathway. Int J Med Sci 2014;11:7-16
   PubMed Web of Science ®Google Scholar
• Wu C, Yang S, Sun Z, et al. Characterization of the Attenuation of Breast Cancer Bone Metastasis in Mice by Zoledronic Acid Using Tc bone Scintigraphy. Pathol Oncol Res 2014;20(3):747-54
   PubMed Web of Science ®Google Scholar
• Charehbili A, van de Ven S, Smit VT, et al. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2 negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Ann Oncol 2014;25(5):998-1004
   PubMed Web of Science ®Google Scholar